Breast MRI for Monitoring of Response to Neoadjuvant Chemotherapy




          MRI is known as the most accurate imaging modality to monitor the response of breast cancer to neoadjuvant chemotherapy (also known as pre-operative chemotherapy). For lesions that present as mass type with well-defined boundaries, MRI is very accurate and can predict residual disease down to several mm. It can be used to monitor the response of metastatic nodes as well. However, for lesions that present as non-mass type (e.g. invasive lobular cancer or invasive ductal cancer with extensive DCIS), the residual disease may break apart into small cell clusters, and difficult to be detected on MRI.